Table 2 Antimyeloma standard of care therapy.

From: LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

SOC treatment, n (%)a

N = 248

Glucocorticoid

220 (88.7)

PI

133 (53.6)

 Carfilzomib

63 (25.4)

 Bortezomib

48 (19.4)

 Ixazomib

22 (8.9)

IMiD

117 (47.2)

 Pomalidomide

74 (29.8)

 Lenalidomide

36 (14.5)

 Thalidomide

7 (2.8)

Alkylating agent

107 (43.1)

 Cyclophosphamide

79 (31.9)

 Bendamustine

16 (6.5)

 Melphalan

15 (6.0)

Anti-CD38 monoclonal antibody

24 (9.7)

 Daratumumab

23 (9.3)

 Isatuximab

1 (0.4)

Anthracyclines

18 (7.3)

Topoisomerase inhibitor

16 (6.5)

Other antineoplastic agentb

15 (6.0)

Histone deacetylase inhibitor

12 (4.8)

Anti-SLAMF7 monoclonal antibody

9 (3.6)

BCMA-targeted antibody-drug conjugate

7 (2.8)

Bcl-2 inhibitor

6 (2.4)

Autologous stem cell transplant

6 (2.4)

Mitotic inhibitor

2 (0.8)

Selective inhibitor of nuclear export

2 (0.8)

  1. BCMA B-cell maturation antigen, Bcl B-cell lymphoma, IMiD immunomodulatory drug, PI proteasome inhibitor, SLAM signaling lymphocytic activation molecule, SOC standard of care.
  2. aThere was a large amount of heterogeneity in the combination therapies. Patients may have been counted in more than one regimen.
  3. bOther antineoplastic agents included cisplatin and rituximab.
Back to article page